On September 28, Shanghai Sipurui Pharmaceutical Technology Co., Ltd. and MSD jointly announced that the two sides have reached an exclusive global licensing agreement for pre-clinical oral administration of the KRAS G12D inhibitor SPR2015. Under the terms of the agreement, Sprite has granted MSD SPR2015 exclusive rights to develop, manufacture and commercialize on a global scale. Sprite will receive a $400 million down payment and be eligible for specific milestone payments relating to development, commercialization, and other activities related to multiple indications. Including the down payment, the total potential value of this transaction could reach up to US$2.13 billion. The deal has been settled.

Zhitongcaijing · 22h ago
On September 28, Shanghai Sipurui Pharmaceutical Technology Co., Ltd. and MSD jointly announced that the two sides have reached an exclusive global licensing agreement for pre-clinical oral administration of the KRAS G12D inhibitor SPR2015. Under the terms of the agreement, Sprite has granted MSD SPR2015 exclusive rights to develop, manufacture and commercialize on a global scale. Sprite will receive a $400 million down payment and be eligible for specific milestone payments relating to development, commercialization, and other activities related to multiple indications. Including the down payment, the total potential value of this transaction could reach up to US$2.13 billion. The deal has been settled.